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Abstracts / Biol Blood Marrow Transplant 19 (2013) S167eS177 S177levels. Additionally, these levels are affected by a common
CYP450 polymorphism, CYP450-2C19. The aim of our pilot
study was to determine effects of therapeutic drug moni-
toring (TDM) and genotyping in achieving desired vor-
iconazole levels for antifungal prophylaxis in the post HCT
period.
Methods: All patients undergoing HCT at Cincinnati Child-
ren's Hospital Medical Center who received voriconazole
between February 2012 and September 2012 were prospec-Figure 1.tively followed. Voriconazole concentrations were drawn
weekly and adjusted until between 1 mg/L and 5.5 mg/L.
Mutational analyses of the most commonmutation CYP2C19
*2 were performed on all patients to determine their geno-
type. All patients were monitored for common side effects of
voriconazole.
Results: Twenty-ﬁve patients received voriconazole as anti-
fungal prophylaxis for a median of 49 days (range 15-196). In
patients with a wild type genotype the median time to
therapeutic level was 30 days, for heterozygotes 47 days and
11 days for patients with variant genotype. Time and dose
required to reach adequate levels showed a trend towards
correlation with CYP2C19 genotyping (Fig 1). Voriconazole
levels showed larger inter-patient variability in wild-type
patients (Fig 1). Five patients had elevations three times
the upper limit of normal, 1 was discontinued fromvoriconazole therapy. Two patients had levels >5.5 mg/L; 1
showed clinical adverse effects.
Conclusions: Our pilot study demonstrates the importance
of rigorous TDM and potential utilization of CYP2C19 gen-
otyping in selecting appropriate voriconazole dosing for
patients. Despite a small number of patients, it appears that
traditional voriconazole dosing of 4 mg/kg/dose every 12
hours may not be sufﬁcient to achieve levels appropriate
for prophylaxis for the majority of patients in the pop-
ulation, leaving such patients susceptible to fungal infec-
tions during their post HCT course, something that we plan
to address in our future studies using genotype speciﬁc
initial dosing.
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Immune dysregulation resulting in autoimmune cyto-
penia is a serious complication of allogeneic stem cell
transplants (SCT). There are few treatment options when
ﬁrst-line and second-line therapies such as steroids, ritux-
imab and IVIG fail to work. Bortezomib is toxic to malig-
nant and normal plasma cells, and has been used to
decrease allo-antibody titers in sensitized solid organ
transplant recipients. We describe a pediatric patient with
history of chronic granulomatous disease who underwent
a matched unrelated donor bone marrow transplant and
developed secondary autoimmune hemolytic anemia
(AIHA) 5 months later. The AIHA transiently improved after
treatment with steroids, rituximab and IVIG. However, after
4 months there was an exacerbation of AIHA, and evidence
of broader autoimmunity with neutropenia, thrombocyto-
penia, and minimal change nephrotic syndrome. In addi-
tion, opportunistic infection with adenovirus and atypical
mycobacteria developed. There was no response of the
immune cytopenias or nephrosis to high-dose steroids,
IVIG, another 4-week course of rituximab, and plasma-
pheresis. Four doses of bortezomib 1.3mg/m2 IV on days +1,
+4, +8, +11 were administered, with concurrent steroids
and plasmapherisis. Bortezomib was well-tolerated with
transient decrease in neutrophil count. Within 1 month,
the reticulocyte count, haptoglobin, bilirubin, and direct
antiglobulin test normalized, accompanied by a decline in
transfusion requirement, resolution of neutropenia, and
improvement in nephrosis. Anemia and thrombocytopenia
did not completely resolve because of adenoviral hemor-
rhagic cystitis, and he ultimately died as a result of the
opportunistic infections. In patients whose autoimmune
cytopenia does not resolve with rituximab, treatment with
bortezomib can rapidly eliminate autoantibody producing
B-cells and plasma cells. Earlier institution of therapy may
result in disease control and avoid the complications of
prolonged immune suppression.
